MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors
暂无分享,去创建一个
Chris Sander | Barry S. Taylor | Haley Hieronymus | C. Sander | H. Hieronymus | W. Gerald | B. Taylor | B. Carver | C. Sawyers | John Wongvipat | N. J. Clegg | William L. Gerald | Charles L. Sawyers | Brett S. Carver | John Wongvipat | Suzana S. Couto | Katharine Ellwood-Yen | S. Couto | Katharine Ellwood-Yen | Nicola J. Clegg
[1] Zhi Hu,et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.
[2] C. García-echeverría,et al. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. , 2009, Current opinion in cell biology.
[3] T. Golub,et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.
[4] Todd R. Golub,et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[5] Q. She,et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. , 2010, Cancer cell.
[6] S. Lowe,et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.
[7] G. Evan,et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB , 1997, Nature.
[8] P. Pandolfi,et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression , 2010, Proceedings of the National Academy of Sciences.
[9] L. Penn,et al. Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.
[10] W. Hahn,et al. Modelling the molecular circuitry of cancer , 2002, Nature Reviews Cancer.
[11] F. Khuri,et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.
[12] W. Isaacs,et al. Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing , 2008, Clinical Cancer Research.
[13] L. Coussens,et al. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity , 2010, Cancer and Metastasis Reviews.
[14] D. Sabatini. mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.
[15] T. Golub,et al. Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells , 2004, Cancer Research.
[16] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[17] M. Karin,et al. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer , 2010, Nature.
[18] D. Bostwick,et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. , 1999, Journal of the National Cancer Institute.
[19] J. Serth,et al. Expression of E-cadherin in primary prostate cancer: correlation with clinical features. , 1998, British journal of urology.
[20] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[21] P. Pandolfi,et al. Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.
[22] H. Scher,et al. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. , 2009, The Lancet. Oncology.
[23] P. Pandolfi,et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.
[24] A. Chinnaiyan,et al. Recurrent gene fusions in prostate cancer , 2008, Nature Reviews Cancer.
[25] J. Blenis,et al. RAS/ERK Signaling Promotes Site-specific Ribosomal Protein S6 Phosphorylation via RSK and Stimulates Cap-dependent Translation* , 2007, Journal of Biological Chemistry.
[26] J. Epstein,et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. , 1999, The American journal of pathology.
[27] C. Sawyers,et al. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. , 2005, Cancer research.
[28] Gordon B Mills,et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.
[29] J. Clohessy,et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. , 2010, The Journal of clinical investigation.
[30] Jun Luo,et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis , 2008, Modern Pathology.
[31] P. Roy-Burman,et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation , 2001, Mechanisms of Development.
[32] Jason A. Koutcher,et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.
[33] D. Guertin,et al. The Pharmacology of mTOR Inhibition , 2009, Science Signaling.
[34] C. Sawyers. Will mTOR inhibitors make it as cancer drugs? , 2003, Cancer cell.
[35] W. Hahn,et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. , 2008, Cancer cell.
[36] I. Tannock,et al. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. , 2005, Cancer research.
[37] J. Blenis,et al. Molecular mechanisms of mTOR-mediated translational control , 2009, Nature Reviews Molecular Cell Biology.
[38] D. Sabatini,et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.
[39] C. Sawyers,et al. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.
[40] R. Amato,et al. Pilot study of rapamycin in patients with hormone-refractory prostate cancer. , 2008, Clinical genitourinary cancer.
[41] H. Scher,et al. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] W. Sellers,et al. Akt-regulated pathways in prostate cancer , 2005, Oncogene.
[43] S. Ben‐Sasson,et al. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.
[44] S Rozen,et al. Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.
[45] K. W. Kim,et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. , 2006, Cancer research.
[46] William C Hahn,et al. MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. , 2009, Cancer research.
[47] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[48] D. Bostwick,et al. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.
[49] S. Abdulkadir,et al. Interactions between Cells with Distinct Mutations in c-MYC and Pten in Prostate Cancer , 2009, PLoS genetics.
[50] T. Graeber,et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.
[51] C. Sander,et al. Functional Copy-Number Alterations in Cancer , 2008, PloS one.
[52] Jianfeng Xu,et al. Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.